ALX Oncology Holdings Inc. (ALXO): Valuation
TTM figures as of June 30, 2026
ALX Oncology Holdings Inc. trades at a -26.45% free-cash-flow yield. That FCF yield is higher than 50% of its own month-end history back to 2020.
Earnings yield -30.15%. ROIC -705.3%. Net cash $126.9M.
74 month-end valuation observations are on file, starting July 2020.
Sector comparison uses 2682 Healthcare names.
Frequently asked questions
Is ALXO cheap versus its own history?
ALX Oncology Holdings Inc. trades at a -26.45% free-cash-flow yield. That FCF yield is higher than 50% of its own month-end history back to 2020.
What is ALXO's free-cash-flow yield?
ALX Oncology Holdings Inc. currently yields -26.45% of market cap as trailing free cash flow.
Where do these valuation figures come from?
Yields and quality metrics are computed from the same SEC TTM figures as the financials page, against the live market cap. Historical bands reconstruct month-end market cap from split-adjusted closes and the share count in the units it was filed, then divide by those dollar totals. Nothing here is a third-party estimate.